MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
shares of common stock...
$6,396,888
Proceeds from issuance of
preferred stock
$6,000,000
Proceeds from issuance of
convertible promissory...
$5,714,800
Proceeds from exercise of
pre-funded warrants
$1,908
Net cash provided by
financing activities
$17,544,131
Canceled cashflow
$569,465
Net increase
(decrease) in cash and cash...
$2,720,875
Canceled cashflow
$14,823,256
Issuance costs
$569,465
Accounts payable and
other current...
$2,848,858
Stock-based compensation
$1,358,082
Change in fair value of
convertible promissory...
-$1,153,421
Prepaid expenses and
other current and non-...
-$667,288
Net cash used in
operating activities
-$14,823,256
Canceled cashflow
$6,027,649
Other income, net
$138,018
Net loss
-$20,848,916
Canceled cashflow
$138,018
Operating lease
right-of-use asset and...
-$1,989
General and
administrative
$10,492,554
Total research and
development
$9,340,959
Change in fair value of
convertible promissory...
-$1,153,421
Back
Back
Cash Flow
source: myfinsight.com
Indaptus Therapeutics, Inc. (INDP)
Indaptus Therapeutics, Inc. (INDP)